Author Correction: Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial - Usmani, Saad Z; Facon, Thierry; Hungria, Vania; Bahlis, Nizar J; Venner, Christopher P; Braunstein, Marc; Pour, Ludek; Martí, Josep M; Basu, Supratik; Cohen, Yael C; Matsumoto, Morio; Suzuki, Kenshi; et al. (Nature medicine, 2025)